Roche entered into an acquisition agreement with Cardion for acquiring rights to Cardion’s interleukin-15 antagonist, CRB-15 for treating rheumatoid arthritis and transplant rejection, thus substantially expanding its product portfolio in the fields of autoimmune diseases and transplantation. The acquisition deal could be worth up to US$90 M to Cardion.